Retrospective multicenter observation study of Pembrolizumab or Pembrolizumab plus chemotherapy in patients with untreated advanced non small-cell lung cancer highly expressing PD-L1

Retrospective multicenter observation study of Pembrolizumab or Pembrolizumab plus chemotherapy in patients with untreated advanced non small-cell lung cancer highly expressing PD-L1 - Retrospective multicenter observation study of Pembrolizumab or Pembrolizumab plus chemotherapy in patients with untreated advanced non small-cell lung cancer highly expressing PD-L1

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040223

Enrollment

300

Registered

2020-05-01

Start date

2020-04-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Histologically or cytologically confirmed NSCLC 2.Highly expressing PD-L1(>50%) 3.Information can be collected with medical records

Exclusion criteria

Exclusion criteria: 1.The positive of EGFR,ALK,ROS-1,BRAF 2.The cases an attending physician determined ineligible. 3.Active concomitant malignancy

Design outcomes

Primary

Measure	Time frame
progression free survival,two year survival rate	—

Secondary

Measure	Time frame
overall survival,response rate,safety	—

Countries

Japan

Contacts

Public ContactYasuyuki Ikezawa

Oji General Hospital Department of Respiratory Medicine

ikezawa0210yasuyuki@gmail.com0144-32-8111

Outcome results